A 72-year-old woman with metastatic pancreatic cancer and ECOG performance status 2 (due to mild neuropathy and fatigue) presents for chemotherapy planning. Which is the preferred first-line regimen for this patient?

Explanation

## First-Line Chemotherapy for Metastatic Pancreatic Cancer with Borderline Performance Status **Key Point:** Gemcitabine + nab-paclitaxel is the preferred regimen for patients with ECOG 1–2 or those unfit for FOLFIRINOX, offering a balance between efficacy and tolerability. ### Clinical Context: ECOG Performance Status Matters ECOG 2 patients (in bed >50% of the day but not bedbound) tolerate intensive chemotherapy poorly. FOLFIRINOX carries unacceptable toxicity in this population, whereas gemcitabine + nab-paclitaxel provides meaningful survival benefit with a more favorable safety profile. ### Evidence Base The MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) trial showed that gemcitabine + nab-paclitaxel improved median OS to 8.5 months versus 6.7 months with gemcitabine monotherapy. This regimen is explicitly recommended for patients with ECOG 1–2 or those unable to tolerate FOLFIRINOX. ### Regimen Characteristics - **Drugs:** Gemcitabine 1000 mg/m² IV + nab-paclitaxel 125 mg/m² IV - **Schedule:** Weekly × 3, then 1 week rest (28-day cycle) - **Toxicity:** Neutropenia, anemia, peripheral neuropathy (manageable), fatigue - **Advantage:** Nab-paclitaxel is albumin-bound, allowing higher drug delivery with lower hypersensitivity risk ### Treatment Selection Algorithm ```mermaid flowchart TD A[Metastatic Pancreatic Cancer]:::outcome --> B{ECOG Status?}:::decision B -->|ECOG 0-1| C[FOLFIRINOX]:::action B -->|ECOG 1-2 or unfit| D[Gemcitabine + nab-paclitaxel]:::action B -->|ECOG 3-4 or very frail| E[Gemcitabine monotherapy or supportive care]:::action C --> F[Median OS 11.1 months]:::outcome D --> G[Median OS 8.5 months]:::outcome E --> H[Median OS 6.0 months]:::outcome ``` **High-Yield:** Gemcitabine + nab-paclitaxel is the "middle ground" regimen — more effective than gemcitabine alone but safer than FOLFIRINOX in patients with borderline performance status or age >70 years. **Clinical Pearl:** Pre-existing peripheral neuropathy (as in this patient) is a relative contraindication to FOLFIRINOX (oxaliplatin-related) but not to nab-paclitaxel, making the latter the safer choice. **Warning:** Do not force FOLFIRINOX into ECOG 2 patients — toxicity (neutropenic fever, diarrhea, neuropathy) often leads to hospitalization and treatment discontinuation, worsening outcomes. [cite:Harrison 21e Ch 297]